Hsbc Holdings PLC Makes New Investment in Illumina, Inc. $ILMN

Hsbc Holdings PLC acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 145,695 shares of the life sciences company’s stock, valued at approximately $25,660,000.

Other institutional investors and hedge funds have also modified their holdings of the company. BlackRock Inc. acquired a new stake in Illumina during the second quarter worth about $3,374,423,000. Primecap Management Co. CA purchased a new stake in Illumina in the 2nd quarter worth approximately $617,981,000. WCM Investment Management LLC grew its stake in shares of Illumina by 45.5% during the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after purchasing an additional 1,851,848 shares during the period. Bank of New York Mellon Corp acquired a new stake in shares of Illumina during the 2nd quarter worth approximately $293,846,000. Finally, Invesco Ltd. increased its holdings in shares of Illumina by 97.0% during the 4th quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company’s stock valued at $360,426,000 after purchasing an additional 1,352,731 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on ILMN shares. Leerink Partners boosted their target price on shares of Illumina from $175.00 to $210.00 and gave the company an “outperform” rating in a research note on Friday, July 17th. Sanford C. Bernstein reiterated a “market perform” rating and issued a $215.00 price objective on shares of Illumina in a research report on Friday, July 31st. Zacks Research raised shares of Illumina from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 3rd. Evercore restated an “outperform” rating on shares of Illumina in a research report on Monday, July 6th. Finally, Piper Sandler restated an “overweight” rating and issued a $225.00 price target (up from $200.00) on shares of Illumina in a research note on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Illumina presently has an average rating of “Hold” and a consensus price target of $188.40.

Insider Transactions at Illumina

In related news, SVP Christensen Jakob Wedel sold 1,033 shares of Illumina stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the sale, the senior vice president directly owned 14,023 shares in the company, valued at approximately $2,685,684.96. The trade was a 6.86% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Scott M. Davies sold 615 shares of the business’s stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $200.00, for a total value of $123,000.00. Following the sale, the insider owned 20,338 shares of the company’s stock, valued at approximately $4,067,600. This trade represents a 2.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 2,034,688 shares of company stock valued at $417,970,281 over the last 90 days. Corporate insiders own 2.90% of the company’s stock.

Illumina Price Performance

Illumina stock opened at $227.69 on Friday. The stock has a market capitalization of $34.38 billion, a P/E ratio of 42.48, a P/E/G ratio of 3.16 and a beta of 1.45. The company’s fifty day moving average price is $192.98 and its 200 day moving average price is $155.18. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. Illumina, Inc. has a 1 year low of $88.00 and a 1 year high of $231.81.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. The company had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The firm’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same period in the prior year, the business posted $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities research analysts anticipate that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.